iShares US Medical Devices

ResMed and Oura Partner to Enhance Sleep Health Education and Care Pathways for US Members

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

Boston Scientific Announces Positive Results from SEISMIQ™ 4CE FRACTURE IDE Trial

FAMAR Group Signs Contract Manufacturing Agreement with GE HealthCare to Expand Iodine Contrast Agent Capacity

Stryker Agrees to Acquire Amplitude Vascular Systems for $835 Million

Boston Scientific Average Stock Price Target Cut to $83.8, Market Maintains Buy Consensus

Edwards Lifesciences EVP Donald E. Bobo Jr. Sells $1.47M in Shares

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Boston Scientific Signs $2 Billion Accelerated Share Repurchase Agreement

Boston Scientific Invests $1.5 Billion for 34% Stake in MiRus with Option to Acquire Balloon-Expandable TAVR System for $3 Billion

GEHC Receives 'Hold' Consensus from 17 Brokers, Executives Buy Shares to Show Confidence

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Stryker partners with Max Smart Hospital to advance surgical training for robotic-assisted joint replacements

NVision Completes $55 Million B Round Led by Abbott to Expand Quantum Computing Platform

Edward Lifesciences CEO Bernard J. Zallouk Sells Shares

Abbott Laboratories Sees Rising Dividend Yield Amid High Legal Costs and Infant Formula Litigation

GE HealthCare to Showcase AI-driven Radiotherapy Tools at ESTRO 2026

GE HealthCare Director Receives Restricted Stock Units and Buys Stocks

BD Medical applies for issuance of 600 million euros of notes

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Boston Scientific announced positive results from the FRACTURE trial for its SEISMIQ 4CE coronary IVL catheter, achieving primary safety and effectiveness goals in severe CAD patients. The trial showed a 93.3% freedom from major adverse cardiac events and a 93.7% procedural success rate. The device aims to improve stent placement by fracturing calcium buildup in arteries. Boston Scientific shares rose 2.27% to $57.19 following the announcement.

benzinga_article

Boston Scientific

SPDR S&P Health Equip

S&P 500

Stellantis NV

ResMed will participate in the 46th Annual William Blair Growth Stock Conference in Chicago on June 2, 2026. CEO Mick Farrell and CFO Aaron Bloomer are scheduled to present at approximately 4:40 p.m. CT.

PUBT

Resmed

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed CEO, CFO to present at William Blair Growth Stock Conference

On May 19, 2026, the S&P 500 closed lower due to rising inflation expectations and higher long-term yields. The healthcare sector outperformed, led by stocks like Becton Dickinson and Eli Lilly, as they are less affected by rising yields. Conversely, the materials sector struggled with declining gold and silver prices, impacted by a stronger dollar, with stocks like Newmont Mining and DuPont seeing losses.

Tip Ranks

Newmont

Becton Dickinson and

iShares US Pharma

Direxion Daily Gold Miners Bull 2X

Health Care Select Sector SPDR

Wisdomtree Efficient Gold Plus Gold Miners Stgy Fd - ETF

iShares MSCI Global Gold Miners

Tradr 2X Long NEM Daily ETF

SPDR S&P Biotech

VanEck Junior Gold Miners ETF

VanEck Gold Miners ETF

Defiance Daily Target 2X Long LLY ETF

Us Gbl GLD & Met

iShares Global Healthcare

Sprott GLD Miners Etf

Baxter

Eli Lilly

DexCom

Bio-Techne

DuPont de Nemours

Martin Marietta Materials

Albemarle

CRH Plc

DUPONT DE NEMOURS INC

Top Stock Gainers Today, 5/19/26

ALGN

Dr. Michael McClain discusses in HelloNation how Invisalign and braces can treat various orthodontic issues, including bite alignment, crowding, and spacing. The article highlights common problems like overbites, crossbites, and open bites, explaining that both treatments can effectively address these concerns. It emphasizes the importance of proper diagnosis and individualized care for optimal outcomes, noting that treatment can begin at different ages and contributes to long-term oral health.

Unusual Whales

Align

In HelloNation, Orthodontics Expert Dr. Michael McClain Details What Orthodontic Problems Invisalign and Braces Can Fix

NXGL

SBIO

NEXGEL shares are trading higher after the company announced data from randomized, 30-patient, single-center Institutional Review Board clinical study.

Nexgel

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM)

AMIX

MTVA

On Tuesday, Med Pharmaceuticals (NASDAQ:INM) saw a 127% increase to $1.54, while MetaVia (NASDAQ:MTVA) rose 58.54% to $1.76. Other gainers included Co-Diagnostics (NASDAQ:CODX) up 41.6% and Edesa Biotech (NASDAQ:EDSA) up 32.11%. Conversely, WORK Medical Tech Gr (NASDAQ:WOK) dropped 39% to $0.23, and Autonomix Medical (NASDAQ:AMIX) fell 25.43%. AIM ImmunoTech (AMEX:AIM) declined 18.02% to $0.33.

Autonomix Medical

WORK Medical Tech

Edesa Biotech

Co-Diagnostics

AIM ImmunoTech

Invesco Nasdaq Biotechnology ETF

Adial Pharmaceuticals

Virax Biolabs

Akanda

Psyence Biomedical

Quantum Cyber NV

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

Mainz Biomed NV

12 Health Care Stocks Moving In Tuesday's Intraday Session

PAVM

Analyst Anthony Vendetti from Maxim Group has reaffirmed a Buy rating on PAVmed, maintaining a price target of $16. He cites the company's expanding oncology platforms, strategic partnerships, and the rollout of the Veris Cancer Care Platform as key factors. Vendetti highlights PAVmed's stake in Lucid Diagnostics and the momentum of EsoGuard testing, along with the relaunch of its medical device portfolio, as supporting elements for his rating.

PAVmed

Lucid Diagnostics

Icecure Medical

Daxor

PAVMED INC C/WTS 30/04/2025(TO PUR COM) CLASS Z

Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16

GEHC

Analysts at Argus have lowered their price target for GE HealthCare Technologies (NASDAQ:GEHC) from $95.00 to $80.00, maintaining a 'buy' rating. Other firms like JPMorgan and Mizuho have also adjusted their targets, with JPMorgan setting it at $65.00. Currently, GEHC's stock trades at $62.05, with an average price target of $80.63 from analysts. The company reported earnings of $0.99 per share, missing estimates, but revenue increased by 7.4% year-over-year.

Market Beat

GE HealthCare Tech

JPMorgan Chase

Mizuho Financial

Mizuho Financial Group, Inc.

BNP Paribas

Evercore

Barclays

GE Aerospace

Honeywell

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Honeywell International - WI

GE HealthCare Technologies (NASDAQ:GEHC) Price Target Cut to $80.00 by Analysts at Argus

Nexalin Technology Inc. (NXL) has acquired PONM Inc. from GreenLight Ventures for $1.3 million, enhancing its HALO Clarity program with AI-integrated remote patient monitoring and virtual clinic management tools. This acquisition supports Nexalin's pivotal trial for moderate-to-severe insomnia, expected to begin in Q2 2026. GreenLight Ventures becomes a significant equity holder and strategic partner, aiding in product and regulatory support. Nexalin's stock closed at $0.32, down 5.26%.

nasdaq

Nexalin Tech

Nasdaq

NEXALIN TECHNOLOGY INC C/WTS 22/09/25(TO PUR COM)

Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trial

513060

On May 19, 2026, the leading sector was the Energy Select Sector SPDR ETF (XLE) with a price change of +0.22%. The Health Care Select Sector SPDR ETF (XLV) also gained slightly. Conversely, the Technology Select Sector SPDR ETF (XLK) led the losses with a decline of -1.95%, followed by the Industrial (XLI) and Consumer Discretionary (XLY) sectors. This data helps traders analyze market trends for better investment decisions.

Bosera Hang Seng Health Care ETF(QDII)

United States Oil Fund LP

Spdr Select Indu

ProShares Ultra Energy

VG Health

SPDR S&P Software

iShares US Oil Equip & Svcs

Ark Genomic Revolution ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

SPDR Energy Select

Pro Ultr Bloomberg Crude Oil

SPDR O&G Ex & Prd

VG Energy

ISHRS S&P Glb Engy

iShares Expanded Tech Software Sector ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

VanEck Oil Services ETF

Spdr Select Tech

SPDR FD Consumer Discretionary

Spdr Material

Real Est Select Spdr

Comm Servcies Select Sector SPDR

Financial Select Sector SPDR Fund

SPDR FD Consumer Staples

Leading And Lagging Sectors For May 19, 2026

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

iShares US Medical Devices(IHI.US)